Literature DB >> 33177060

Lower Airway Dysbiosis Affects Lung Cancer Progression.

Jun-Chieh J Tsay1,2, Benjamin G Wu1,2, Imran Sulaiman1, Katherine Gershner3, Rosemary Schluger1, Yonghua Li1, Ting-An Yie1, Peter Meyn4, Evan Olsen1, Luisannay Perez1, Brendan Franca1, Joseph Carpenito1, Tadasu Iizumi1, Mariam El-Ashmawy5, Michelle Badri6, James T Morton7, Nan Shen8, Linchen He9, Gaetane Michaud1, Samaan Rafeq1, Jamie L Bessich1, Robert L Smith2, Harald Sauthoff2, Kevin Felner2, Ray Pillai1, Anastasia-Maria Zavitsanou10, Sergei B Koralov10, Valeria Mezzano10, Cynthia A Loomis10, Andre L Moreira10, William Moore11, Aristotelis Tsirigos10, Adriana Heguy4,10, William N Rom1, Daniel H Sterman1, Harvey I Pass12, Jose C Clemente8, Huilin Li9, Richard Bonneau6,7,13, Kwok-Kin Wong14, Thales Papagiannakopoulos10, Leopoldo N Segal15.   

Abstract

In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly occurs, and ex vivo models support that some of these bacteria can trigger host transcriptomic signatures associated with carcinogenesis. Here, we show that this lower airway dysbiotic signature was more prevalent in the stage IIIB-IV tumor-node-metastasis lung cancer group and is associated with poor prognosis, as shown by decreased survival among subjects with early-stage disease (I-IIIA) and worse tumor progression as measured by RECIST scores among subjects with stage IIIB-IV disease. In addition, this lower airway microbiota signature was associated with upregulation of the IL17, PI3K, MAPK, and ERK pathways in airway transcriptome, and we identified Veillonella parvula as the most abundant taxon driving this association. In a KP lung cancer model, lower airway dysbiosis with V. parvula led to decreased survival, increased tumor burden, IL17 inflammatory phenotype, and activation of checkpoint inhibitor markers. SIGNIFICANCE: Multiple lines of investigation have shown that the gut microbiota affects host immune response to immunotherapy in cancer. Here, we support that the local airway microbiota modulates the host immune tone in lung cancer, affecting tumor progression and prognosis.See related commentary by Zitvogel and Kroemer, p. 224.This article is highlighted in the In This Issue feature, p. 211. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 33177060      PMCID: PMC7858243          DOI: 10.1158/2159-8290.CD-20-0263

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  91 in total

1.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

2.  PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ.

Authors:  Yutaka Kurebayashi; Shigenori Nagai; Ai Ikejiri; Masashi Ohtani; Kenji Ichiyama; Yukiko Baba; Taketo Yamada; Shohei Egami; Takayuki Hoshii; Atsushi Hirao; Satoshi Matsuda; Shigeo Koyasu
Journal:  Cell Rep       Date:  2012-03-29       Impact factor: 9.423

3.  Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism.

Authors:  Min Cheng; Liting Qian; Guodong Shen; Geng Bian; Tingjuan Xu; Weiping Xu; Gan Shen; Shilian Hu
Journal:  Cancer Res       Date:  2014-06-19       Impact factor: 12.701

4.  The Sequence Read Archive: explosive growth of sequencing data.

Authors:  Yuichi Kodama; Martin Shumway; Rasko Leinonen
Journal:  Nucleic Acids Res       Date:  2011-10-18       Impact factor: 16.971

5.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

6.  Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals.

Authors:  Christine M Bassis; John R Erb-Downward; Robert P Dickson; Christine M Freeman; Thomas M Schmidt; Vincent B Young; James M Beck; Jeffrey L Curtis; Gary B Huffnagle
Journal:  MBio       Date:  2015-03-03       Impact factor: 7.867

7.  Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung.

Authors:  Leopoldo N Segal; Jose C Clemente; Benjamin G Wu; William R Wikoff; Zhan Gao; Yonghua Li; Jane P Ko; William N Rom; Martin J Blaser; Michael D Weiden
Journal:  Thorax       Date:  2016-08-02       Impact factor: 9.139

8.  Establishing microbial composition measurement standards with reference frames.

Authors:  James T Morton; Clarisse Marotz; Alex Washburne; Justin Silverman; Livia S Zaramela; Anna Edlund; Karsten Zengler; Rob Knight
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

9.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Authors:  Stephan Sauer; Ludovica Bruno; Arnulf Hertweck; David Finlay; Marion Leleu; Mikhail Spivakov; Zachary A Knight; Bradley S Cobb; Doreen Cantrell; Eric O'Connor; Kevan M Shokat; Amanda G Fisher; Matthias Merkenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

10.  Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Authors:  Rodrigo Romero; Volkan I Sayin; Shawn M Davidson; Matthew R Bauer; Simranjit X Singh; Sarah E LeBoeuf; Triantafyllia R Karakousi; Donald C Ellis; Arjun Bhutkar; Francisco J Sánchez-Rivera; Lakshmipriya Subbaraj; Britney Martinez; Roderick T Bronson; Justin R Prigge; Edward E Schmidt; Craig J Thomas; Chandra Goparaju; Angela Davies; Igor Dolgalev; Adriana Heguy; Viola Allaj; John T Poirier; Andre L Moreira; Charles M Rudin; Harvey I Pass; Matthew G Vander Heiden; Tyler Jacks; Thales Papagiannakopoulos
Journal:  Nat Med       Date:  2017-10-02       Impact factor: 53.440

View more
  29 in total

Review 1.  Redrawing therapeutic boundaries: microbiota and cancer.

Authors:  Jonathan Sholl; Gregory D Sepich-Poore; Rob Knight; Thomas Pradeu
Journal:  Trends Cancer       Date:  2021-11-26

Review 2.  The Cancer Microbiome: Recent Highlights and Knowledge Gaps.

Authors:  Reece J Knippel; Julia L Drewes; Cynthia L Sears
Journal:  Cancer Discov       Date:  2021-08-16       Impact factor: 39.397

3.  Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome.

Authors:  Imran Sulaiman; Matthew Chung; Luis Angel; Jun-Chieh J Tsay; Benjamin G Wu; Stephen T Yeung; Kelsey Krolikowski; Yonghua Li; Ralf Duerr; Rosemary Schluger; Sara A Thannickal; Akiko Koide; Samaan Rafeq; Clea Barnett; Radu Postelnicu; Chang Wang; Stephanie Banakis; Lizzette Pérez-Pérez; Guomiao Shen; George Jour; Peter Meyn; Joseph Carpenito; Xiuxiu Liu; Kun Ji; Destiny Collazo; Anthony Labarbiera; Nancy Amoroso; Shari Brosnahan; Vikramjit Mukherjee; David Kaufman; Jan Bakker; Anthony Lubinsky; Deepak Pradhan; Daniel H Sterman; Michael Weiden; Adriana Heguy; Laura Evans; Timothy M Uyeki; Jose C Clemente; Emmie de Wit; Ann Marie Schmidt; Bo Shopsin; Ludovic Desvignes; Chan Wang; Huilin Li; Bin Zhang; Christian V Forst; Shohei Koide; Kenneth A Stapleford; Kamal M Khanna; Elodie Ghedin; Leopoldo N Segal
Journal:  Nat Microbiol       Date:  2021-08-31       Impact factor: 17.745

Review 4.  Lung microbial-host interface through the lens of multi-omics.

Authors:  Shivani Singh; Jake G Natalini; Leopoldo N Segal
Journal:  Mucosal Immunol       Date:  2022-07-06       Impact factor: 8.701

5.  Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions.

Authors:  Lian Narunsky-Haziza; Gregory D Sepich-Poore; Ilana Livyatan; Omer Asraf; Cameron Martino; Deborah Nejman; Nancy Gavert; Jason E Stajich; Guy Amit; Antonio González; Stephen Wandro; Gili Perry; Ruthie Ariel; Arnon Meltser; Justin P Shaffer; Qiyun Zhu; Nora Balint-Lahat; Iris Barshack; Maya Dadiani; Einav N Gal-Yam; Sandip Pravin Patel; Amir Bashan; Austin D Swafford; Yitzhak Pilpel; Rob Knight; Ravid Straussman
Journal:  Cell       Date:  2022-09-29       Impact factor: 66.850

6.  Saliva and Lung Microbiome Associations with Electronic Cigarette Use and Smoking.

Authors:  Ewy A Mathe; Peter G Shields; Kevin L Ying; Theodore M Brasky; Jo L Freudenheim; Joseph P McElroy; Quentin A Nickerson; Min-Ae Song; Daniel Y Weng; Mark D Wewers; Noah B Whiteman
Journal:  Cancer Prev Res (Phila)       Date:  2022-07-05

7.  Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2.

Authors:  Qingsheng Li; Kevin E Goggin; SeonYeong Seo; Jonathan M Warawa; Nejat K Egilmez
Journal:  Cancer Immunol Immunother       Date:  2022-09-08       Impact factor: 6.630

Review 8.  The microbiome and human cancer.

Authors:  Gregory D Sepich-Poore; Laurence Zitvogel; Ravid Straussman; Jeff Hasty; Jennifer A Wargo; Rob Knight
Journal:  Science       Date:  2021-03-26       Impact factor: 47.728

9.  Lung microbiome alterations in NSCLC patients.

Authors:  Leliang Zheng; Ruizheng Sun; Yinghong Zhu; Zheng Li; Xiaoling She; Xingxing Jian; Fenglei Yu; Xueyu Deng; Buqing Sai; Lujuan Wang; Wen Zhou; Minghua Wu; Guiyuan Li; Jingqun Tang; Wei Jia; Juanjuan Xiang
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 10.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.